BofA Merrill Lynch’s Sumant S. Kulkarni maintained a Buy rating on Allergen, with a price objective of $385.
Even if the deal with Pfizer does not come through, Allergen is poised to grow organically as well as strengthen its balance sheet, Kulkarni said.
"They are in discussion with FDA regarding making it a registration directed trial.".....been said for 6 months at least. But I do appreciate what you add here as always Tar. As the old saying goes if you're going to talk the talk, need to walk the walk...Ali hasn't done it to date. He constantly commits one of the oldest sins in business; over promises, under delivers. Ok had my moment(s) to vent. Back to waiting......hoping.
The unfortunate thing is, I really thought this guy was the answer but he's used all his goodwill capital with consistently missed goals and now has one heck of a hole to climb from. jmo
Not sure why people feel PII 907 is starting this year. As anyone knows, Ali promised 5 things in January's presentation and 4 of them are guaranteed not to happen. Just go to the clinicaltrials.gov site and look at the completion date for PI for 907. Need I say more?
The show was primarily about Hillary's attack on pricing and TGTX was but an example for that. It appears he was so excited to be on the show he failed to show leadership and steer Cramer away from that topic and to selling the company. A small bump; the great products remain in motion.
Sentiment: Strong Buy
New pipeline of Immuno-oncology drug candidates: exclusive, multi-year
partnership with Aurigene
PD-L1, orally available small molecule antagonist: IND filing expected in 2015.
Let's hope Ali has 907 PII news in 2 weeks for us. It would be nice to see him hit some of the goals he laid out in January for this year. Getting late in the game. From 1/21 presentation...
Precision drug candidates to address hematologic cancers
CUDC-907: Phase 1, active in diffuse large B cell lymphoma. Phase 2 expected in 2015
IRAK4, orally available small molecule antagonist : IND filing expected in 2015
CUDC-427: Phase 1, focusing clinical studies in lymphoma (DLBCL, MALT)
CUDC-305 (Debio 0932): expect Phase 2 trial in systemic mastocytosis in 2015